Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say

Executive Summary

Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.

You may also be interested in...



Building A Biosimilars Market: Lessons From The US Launches

Provider trust in the biosimilar is as important as price in the nascent market and biosimilars need more commercialization support than innovators to obtain it, executives from AmerisourceBergen advise.

Building A Biosimilars Market: Lessons From The US Launches

Provider trust in the biosimilar is as important as price in the nascent market and biosimilars need more commercialization support than innovators to obtain it, executives from AmerisourceBergen advise.

Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'

Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel